Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Recurrent or Metastatic Head and Neck Cancer
NCT00024089Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jul 2001
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in head and neck squamous cell carcinoma (HNSCC), sponsored by National Cancer Institute. Primary endpoint: Disease Control Rate. Started Jul 2001; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00024089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024089.